AB0269 Ankle synovitis and treat-to-target strategy in clinically and serologically different forms of rheumatoid arthritis, a single-centre experience

Background DAS28 based treat-to-target (T2T) strategy1 was shown to improve outcomes in patients with rheumatoid arthritis (RA). Although previous studies have shown that approximately 1/3 of RA patients have foot symptoms[,2 ankle and foot joints are not included in DAS28. Objectives To study the prevalence of ankle synovitis in clinically and serologically different forms of RA, treated according to the updated T2T strategy. Methods 1109 patients, with RA, treated according to the T2T approach were included in this study. Concurrent tenderness and swelling of the ankle joint were considered as synovitis. Rheumatoid factor (RF) and anti-mutated citrullinated vimentin (anti-MCV) positive and negative patients with different disease activity were evaluated. Results 8.47% (94) patients had high (DAS28 >5.1); 35.25% (391) moderate (DAS28 ≤5.1;>3.2) and 18.66% (207) low (DAS28 ≤3.2;≥2.6) disease activity. 37,6% (417) of patients were in clinical remission (DAS28 Conclusions Our present data show that ankle synovitis is rather common in patients with serologically and clinically different forms of RA and highlight the importance of careful medical examination, even in case of clinical remission. References [1] Smolen JS, et al. Ann Rheum Dis. 2016Jan;75(1):3–15. [2] Dixey J, et al. J Rheumatol2004;69:48–54. Disclosure of Interest None declared